A comparative analysis of recurrence risk predictions in ER+/HER2− early breast cancer using NHS Nottingham Prognostic Index, PREDICT, and CanAssist Breast

Aims Clinicians use multi-gene/biomarker prognostic tests and free online tools to optimize treatment in early ER+/HER2− breast cancer. Here we report the comparison of recurrence risk predictions by CanAssist Breast (CAB), Nottingham Prognostic Index (NPI), and PREDICT along with the differences in...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Breast cancer research and treatment 2022-11, Vol.196 (2), p.299-310
Hauptverfasser:	Gunda, Aparna, Eshwaraiah, Mallikarjuna S., Gangappa, Kiran, Kaur, Taranjot, Bakre, Manjiri M.
Format:	Artikel
Sprache:	eng
Schlagworte:	Breast cancer Breast Neoplasms - diagnosis Breast Neoplasms - genetics Breast Neoplasms - therapy Cancer Chemotherapy Clinical Trial Comparative analysis ErbB-2 protein Female Humans Medical research Medicine Medicine & Public Health Medicine, Experimental Oncology Patients Prognosis Retrospective Studies Risk Risk groups State Medicine
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	Aims Clinicians use multi-gene/biomarker prognostic tests and free online tools to optimize treatment in early ER+/HER2− breast cancer. Here we report the comparison of recurrence risk predictions by CanAssist Breast (CAB), Nottingham Prognostic Index (NPI), and PREDICT along with the differences in the performance of these tests across Indian and European cohorts. Methods Current study used a retrospective cohort of 1474 patients from Europe, India, and USA. NPI risk groups were categorized into three prognostic groups, good (GPG-NPI index ≤ 3.4) moderate (MPG 3.41–5.4), and poor (PPG > 5.4). Patients with chemotherapy benefit of
ISSN:	0167-6806 1573-7217 1573-7217
DOI:	10.1007/s10549-022-06729-7